1-isopropyl-6-methyl-9,10-didehydroergoline-8β-methanamine | 1026542-87-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1-isopropyl-6-methyl-9,10-didehydroergoline-8β-methanamine
• 英文别名: [(6aR,9S)-7-methyl-4-propan-2-yl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinolin-9-yl]methanamine
• CAS: 1026542-87-9
• 化学式: C₁₉H₂₅N₃
• 分子量: 295.428
• InChiKey: WJSPHCVIJJNMEF-SCLBCKFNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  34.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-isopropyl-6-methyl-9,10-didehydroergoline-8β-methanamine 在 氨 、 苯酚 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 8β-(3,5-dioxopiperazin-1-ylmethyl)-1-isopropyl-9,10-didehydro-6-methylergoline
  参考文献：
  名称：

  D1 Agonist and/or D2 antagonist dopamine receptor properties of a series of ergoline derivatives: a structure–activity study

  摘要：

  A series of (3,5-dioxopiperazin-1-yl)ergoline derivatives has been synthesised and evaluated in vitro and in vivo for their dopaminergic D-1 and D-2 components. The structural contributions to the pharmacological profile of the ergoline skeleton, its substituents on positions 1, 2, 6, 9, and the 3,5-dioxopiperazin-1-yl portion of the molecule were examined. Structure-activity relationships within this series suggested that substitution on the ergoline skeleton in position 1 or 2 and on the 3,5-dioxopiperazin-4-nitrogen generated compounds with a spectrum of dopamine agonistic/antagonistic activity sensitive to both the nature and position of substituents. (C) Elsevier, Paris.

  DOI：

  10.1016/s0223-5234(99)80045-2
• 作为产物：
  描述：

  [(6aR,9R)-7-methyl-4-propan-2-yl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinolin-9-yl]methanol 在 一水合肼 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 2.0h， 生成 1-isopropyl-6-methyl-9,10-didehydroergoline-8β-methanamine
  参考文献：
  名称：

  D1 Agonist and/or D2 antagonist dopamine receptor properties of a series of ergoline derivatives: a structure–activity study

  摘要：

  A series of (3,5-dioxopiperazin-1-yl)ergoline derivatives has been synthesised and evaluated in vitro and in vivo for their dopaminergic D-1 and D-2 components. The structural contributions to the pharmacological profile of the ergoline skeleton, its substituents on positions 1, 2, 6, 9, and the 3,5-dioxopiperazin-1-yl portion of the molecule were examined. Structure-activity relationships within this series suggested that substitution on the ergoline skeleton in position 1 or 2 and on the 3,5-dioxopiperazin-4-nitrogen generated compounds with a spectrum of dopamine agonistic/antagonistic activity sensitive to both the nature and position of substituents. (C) Elsevier, Paris.

  DOI：

  10.1016/s0223-5234(99)80045-2